Back to search results

Continuous Glucose Monitoring for Type 2 Diabetes in Underserved Populations

This study is looking at how Continuous Glucose Monitoring (CGM) can help people with Type 2 diabetes who are uninsured or on Medicaid. CGM devices are small sensors placed under the skin that measure blood sugar levels constantly. You might be able to join if you are 18-75 years old, have Type 2 diabetes, have an HbA1c (a measure of average blood sugar over 2-3 months) of 7.5% or higher, and take at least one insulin injection daily. The study wants to see if using CGM helps lower HbA1c levels over 6 months. This is a pilot study to see if this type of research can be done successfully in this community before a larger study is planned. The current recruitment status is unclear.

Study design
This is a randomized open-label study with 50 participants. You would be randomly assigned to either use a Continuous Glucose Monitor or self-monitor your blood sugar.
What's involved
You would participate in the study for 6 months, with visits at the beginning and end. If assigned to the CGM group, you would have a new sensor placed every 14 days. All participants will receive diabetes education.
Compensation
Not stated in the trial record.
Follow-up
After the 6-month study, participants in the self-monitoring group will have the option to wear a CGM sensor for an additional 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07135531

Continuous Glucose Monitoring (CGM) in an Underserved Population

Recruiting
NAAges 18–75InterventionalPrevention
Tulane University
~50 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Continuous Glucose Monitoring (CGM)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Glycated hemoglobin (HbA1c) between baseline and 6-month visits for both groups
Measured over Baseline, 6 months

Conditions

Diabetes
Diabetes Mellitus
Diabetes Type 2

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Louisiana1

Study leadership

  • Shaveta Gupta, MD · PRINCIPAL_INVESTIGATOR · Tulane University

Who to contact

Neha Upadhyay, BDS,MPH
[email protected]
5049889803
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-75 years
Type 2 diabetes mellitus
HbA1C ≥ 7.5%
At least on 1 insulin injection therapy daily
Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas
Patients with Medicaid or free care or uninsured
Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study

Exclusion

Type 1 diabetes mellitus
Currently on CGM or using insulin pump
Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) \<40
Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate
The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement
Pregnant

What this trial measures

  • Change in Glycated hemoglobin (HbA1c) between baseline and 6-month visits for both groupsBaseline, 6 months

    The investigators will take blood samples at baseline and at the 6 months visit to measure the HbA1c levels. Change in the level of HbA1c at 6 months will be compared between the 2 groups to assess the outcome.